- • Imdelltra plus durvalumab extended median overall survival to 21.1 months vs 12.7 months for monotherapy • Grade 3+ adverse events reported at 20.9% for combination vs 10.8% for monotherapy • Safety profile remains consistent with known individual medicine profiles
?? Positive AI Sentiment (+6.5 / 10)